⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11290924 | 0.84 | KMT2A (0.73) | — | |
| SCHEMBL23581543 | 0.84 | KMT2A (0.73) | — | |
| SCHEMBL8850002 | 0.84 | KMT2A (0.73) | — | |
| SCHEMBL605282 | 0.81 | — | — | |
| SCHEMBL2123224 | 0.79 | — | — | |
| SCHEMBL1276454 | 0.78 | KMT2A (0.65) | — | |
| SCHEMBL82293 | 0.78 | — | — | |
| SCHEMBL82294 | 0.78 | — | — | |
| SCHEMBL3461578 | 0.77 | TSHR (0.39) | — | |
| SCHEMBL3462764 | 0.77 | TSHR (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609633-B2 | Core 2 GlcNAc-T inhibitors | MS THERAPEUTICS LIMITED (GB) | 2013-12-17 | — | — | US | claimed |
| US-20120142620-A1 | CORE 2 GLCNAC-T INHIBITORS | BTG INTERNATIONAL LIMITED (GB) | 2012-06-07 | — | — | US | claimed |
| US-20100048496-A1 | Core 2 GlcNAc-T inhibitors | BTG INTERNATIONAL LIMITED (GB) | 2010-02-25 | — | — | US | claimed |
| EP-1802293-A4 | ORALLY EFFECTIVE CANNABINOID ANALOGS | PHARMOS CORP (US) | 2009-04-29 | — | — | EP | claimed |
| EP-1919486-A2 | CORE 2 GLCNAC-T INHIBITORS | BTG INTERNATIONAL LIMITED (GB) | 2008-05-14 | — | — | EP | claimed |
| EP-1802293-A2 | ORALLY EFFECTIVE CANNABINOID ANALOGS | PHARMOS CORPORATION (US) | 2007-07-04 | — | — | EP | claimed |
| US-20070010461-A1 | Core 2 GlcNAc-T inhibitors | BTG INTERNATIONAL LIMITED (GB) | 2007-01-11 | — | — | US | claimed |
| WO-2007003948-A2 | CORE 2 GLCNAC-T INHIBITORS | BTG INTERNATIONAL LIMITED (GB) | 2007-01-11 | — | — | WO | claimed |
| WO-2006043260-A2 | ORALLY EFFECTIVE CANNABINOID ANALOGS | PHARMOS CORPORATION (US) | 2006-04-27 | — | — | WO | claimed |
| EP-0195668-B1 | CARBACYCLIN DERIVATIVES | SANKYO COMPANY LIMITED (JP) | 1991-05-15 | — | — | EP | claimed |
| EP-0195668-A2 | Carbacyclin derivatives | SANKYO COMPANY LIMITED (JP) | 1986-09-24 | — | — | EP | claimed |
| JP-62000016-A | — | — | None | — | — | JP | disclosed |
| JP-63218643-A | — | — | None | — | — | JP | disclosed |
| CN-114126606-B | Method for dispersing a biofilm comprising gram-negative bacteria | Q生物股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2023172606-A1 | IMPROVED FOAMING BIOSURFACTANTS | LOCUS SOLUTIONS IPCO, LLC (US) | 2023-09-14 | — | — | WO | disclosed |
| EP-0128028-A2 | Cephalosporin derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1984-12-12 | — | — | EP | disclosed |
| US-4139720-A | Process for the preparation of aldehydes | HOFFMANN-LA ROCHE INC. (US) | 1979-02-13 | — | — | US | disclosed |
| US-4123464-A | Process for the preparation of aldehydes | HOFFMANN-LA ROCHE INC. (US) | 1978-10-31 | — | — | US | disclosed |
| US-4073811-A | Process for the preparation of aldehydes | HOFFMANN-LA ROCHE INC. (US) | 1978-02-14 | — | — | US | disclosed |
| US-4016212-A | Process for the preparation of aldehydes | HOFFMANN-LA ROCHE INC. (US) | 1977-04-05 | — | — | US | disclosed |